Hard to Treat Diseases Inc. (HTDS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.56: the stock has moved about 44% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHard to Treat Diseases Inc. (HTDS) trades at $0.00002. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for HTDS: HTDS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Hard to Treat Diseases Inc. (HTDS) Healthcare & Pipeline Overview
Hard to Treat Diseases Inc., based in China, develops, manufactures, and distributes biopharmaceuticals and vaccines internationally, focusing on emerging markets; its diverse product portfolio and established sales network provide a foundation for growth amidst increasing global healthcare demands, though it faces competition and regulatory hurdles common in the biotech sector.
What Is the Investment Thesis for HTDS?
Hard to Treat Diseases Inc. presents an investment opportunity driven by its diverse portfolio of biopharmaceuticals and vaccines, targeting high-growth emerging markets. The company's established sales network in South Asia, South-east Asia, Central and South America, and the Middle East provides a platform for expansion. With a gross margin of 28.9% and a profit margin of 15.8%, HTDS showcases its ability to generate profit. However, investors may want to evaluate the risks associated with operating in the highly regulated pharmaceutical industry, including potential challenges related to product approvals, competition, and intellectual property protection. The company's debt-to-equity ratio of 20.63 indicates a moderate level of financial leverage.
Based on FMP financials and quantitative analysis
HTDS Key Highlights
Gross Margin of 28.9% indicates the company's efficiency in managing production costs.
- Profit Margin of 15.8% demonstrates the company's ability to generate profit after all expenses.
- Debt-to-Equity Ratio of 20.63 suggests a conservative approach to financial leverage.
- Beta of 0.56 indicates lower volatility compared to the overall market.
- Focus on emerging markets provides access to high-growth regions with increasing healthcare demands.
Who Are HTDS's Competitors?
HTDS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | — |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | — |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | — |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | — |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | — |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | — |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | — |
| CRMD CorMedix Inc. | $7.19 | -3.10% | $564M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HTDS's Key Strengths?
Diverse product portfolio of biopharmaceuticals and vaccines.
- Established sales network in emerging markets.
- Manufacturing capabilities for both biological and chemical products.
- Experience in navigating regulatory approvals in multiple countries.
What Are HTDS's Weaknesses?
Limited presence in developed markets.
- Dependence on a few key products.
- Potential for generic competition.
- Exposure to currency fluctuations.
What Are the Key Risks for HTDS?
Increasing competition from generic drug manufacturers.
- Changes in government regulations.
- Product liability claims.
- Economic downturns in emerging markets.
- Currency fluctuations impacting profitability.
What Are HTDS's Competitive Advantages?
- Established sales network in emerging markets.
- Diverse product portfolio of biopharmaceuticals and vaccines.
- Manufacturing capabilities for both biological and chemical products.
- Experience in navigating regulatory approvals in multiple countries.
What Does HTDS Do?
Founded in 2009 and headquartered in Shenzhen, China, Hard to Treat Diseases Inc. operates as a manufacturer, supplier, and exporter of biopharmaceuticals and vaccines. The company's product portfolio spans a range of therapeutic areas, including cardiovascular diseases, infectious diseases, and other medical conditions. Key biological products include reteplase (rPA), mycobacterium vaccae, acutobin urinary kallidinogenase, ulinastatin, and cerebroprotein hydrolysate for injection. The company also offers a variety of chemicals, such as cobratide injection, entecavir capsule, HES, dasatinib tablets, thymosin a1 for injection, imipenem and cilastatin sodium for injection, and meropenem for injection. Furthermore, Hard to Treat Diseases Inc. produces vaccines against rabies, meningococcal disease (ACYW135), influenza, Hepatitis A, and varicella. The company distributes its products through a sales network targeting South Asia, South-east Asia, Central and South America, and the Middle East, reflecting a strategic focus on emerging markets. This diversified product offering and geographic reach aim to address unmet medical needs in regions with growing healthcare demands.
What Products and Services Does HTDS Offer?
- Manufactures biopharmaceuticals and vaccines.
- Supplies biopharmaceuticals and vaccines.
- Exports biopharmaceuticals and vaccines.
- Offers biological products like reteplase (rPA) and mycobacterium vaccae.
- Provides chemical products like cobratide injection and entecavir capsule.
- Produces vaccines for rabies, meningococcal disease, influenza, Hepatitis A, and varicella.
- Markets products through a sales network in South Asia, South-east Asia, Central and South America, and the Middle East.
How Does HTDS Make Money?
- Develops and manufactures a range of biopharmaceuticals and vaccines.
- Sells products through a direct sales force and distribution network.
- Targets emerging markets with high unmet medical needs.
- Focuses on both biological and chemical products, as well as vaccines.
What Industry Does HTDS Operate In?
Hard to Treat Diseases Inc. operates within the global biotechnology industry, which is characterized by rapid innovation, intense competition, and stringent regulatory oversight. The industry is driven by increasing healthcare needs, aging populations, and advancements in medical technology. Key trends include the development of novel therapies, personalized medicine, and biosimilars. Hard to Treat Diseases Inc.'s focus on emerging markets positions it to capitalize on the growing demand for affordable medicines and vaccines in these regions. However, the company faces competition from both multinational pharmaceutical companies and local manufacturers.
Who Are HTDS's Key Customers?
- Hospitals and clinics in China and internationally.
- Pharmacies and drugstores.
- Government healthcare agencies.
- Patients requiring biopharmaceutical treatments and vaccines.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Hard to Treat Diseases Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Clearwater, US. HTDS has traded publicly since 1998.
HTDS Financials
HTDS Latest News
No recent news available for HTDS.
HTDS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HTDS.
Price Targets
Wall Street price target analysis for HTDS.
HTDS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HTDS; grades run from A+ (80-100) to F (below 30).
Leadership: Shimin Yuan
CEO
Shimin Yuan is the Chief Executive Officer of Hard to Treat Diseases Inc. His background includes extensive experience in the pharmaceutical industry, with a focus on international business development and strategic partnerships. Prior to joining Hard to Treat Diseases Inc., Mr. Yuan held leadership positions at several multinational pharmaceutical companies, where he was responsible for expanding market access and driving revenue growth in emerging markets. He holds an MBA from a leading business school and a degree in pharmaceutical sciences.
Track Record: Under Shimin Yuan's leadership, Hard to Treat Diseases Inc. has expanded its presence in key emerging markets and launched several new products. He has focused on strengthening the company's sales network and building strategic partnerships to drive growth. Key milestones include increasing revenue by 15% year-over-year and expanding the company's product portfolio to include new vaccines and biopharmaceutical therapies.
HTDS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Hard to Treat Diseases Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in OTC Other stocks carries significantly higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in HTDS.
- Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
- Lack of regulatory oversight increases the risk of fraud and manipulation.
- The company may not meet the minimum financial standards of higher-tier exchanges.
- OTC Other stocks are generally more volatile than stocks listed on major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC Other stocks.
- Check for any regulatory actions or legal proceedings against the company.
- The company has been in operation since 2009.
- The company manufactures and distributes biopharmaceuticals and vaccines.
- The company has an established sales network in emerging markets.
What Investors Ask About Hard to Treat Diseases Inc. (HTDS) — Healthcare
What does Hard to Treat Diseases Inc. do?
Hard to Treat Diseases Inc. is a biopharmaceutical company that manufactures, supplies, and exports a range of biologicals, chemicals, and vaccines.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Financial data is limited due to OTC status.